Literature DB >> 18060598

A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

J J Knox1, X E Chen, R Feld, M Nematollahi, R Cheiken, G Pond, J A Zwiebel, S Gill, M Moore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18060598     DOI： 10.1007/s10637-007-9104-1

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  11 in total

1.  Taxol induced Bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line.

Authors:  S C Cheng; D Luo; Y Xie
Journal:  Cell Biol Int       Date:  2001       Impact factor: 3.612

Review 2.  Apoptosis in liver diseases--detection and therapeutic applications.

Authors:  Saeid Ghavami; Mohammad Hashemi; Kamran Kadkhoda; Seyed Moayed Alavian; Graham H Bay; Marek Los
Journal:  Med Sci Monit       Date:  2005-11

3.  Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels.

Authors:  D Luo; S C Cheng; H Xie; Y Xie
Journal:  Tumour Biol       Date:  1999 Nov-Dec

4.  Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.

Authors:  D E Lopes de Menezes; N Hudon; N McIntosh; L D Mayer
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

Review 5.  Apoptosis in diseases of the liver.

Authors:  M G Neuman
Journal:  Crit Rev Clin Lab Sci       Date:  2001-04       Impact factor: 6.250

6.  Primary liver cancer. An Eastern Cooperative Oncology Group Trial.

Authors:  G Falkson; J M MacIntyre; C G Moertel; L A Johnson; R C Scherman
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

7.  Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma.

Authors:  Cheng-Tang Chiu; Ta-Sen Yeh; Jui-Chen Hsu; Mün-Fu Chen
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

Review 8.  Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.

Authors:  S J Korsmeyer; J R Shutter; D J Veis; D E Merry; Z N Oltvai
Journal:  Semin Cancer Biol       Date:  1993-12       Impact factor: 15.707

9.  Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.

Authors:  C L Lai; P C Wu; G C Chan; A S Lok; H J Lin
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

10.  Induction of remission in hepatocellular carcinoma with doxorubicin.

Authors:  P J Johnson; R Williams; H Thomas; S Sherlock; I M Murray-Lyon
Journal:  Lancet       Date:  1978-05-13       Impact factor: 79.321
View more
  4 in total

1.  Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.

Authors:  Martin-Walter Welker; Joerg Trojan
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

Review 2.  Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Authors:  Min H Kang; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

3.  Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA.

Authors:  Jianjun Zhang; Shenglin Huang; He Zhang; Haibo Wang; Haiyan Guo; Guanxiang Qian; Xianqun Fan; Jian Lu; Andrew R Hoffman; Ji-Fan Hu; Shengfang Ge
Journal:  Int J Cancer       Date:  2010-05-01       Impact factor: 7.396

Review 4.  Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

Authors:  Martin-Walter Welker; Joerg Trojan
Journal:  Cancer Manag Res       Date:  2013-10-08       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.